Related Experiment Video
Updated: Jun 12, 2026

Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms
Published on: August 4, 2023
Treatment of Acinetobacter infections
1Division of Infectious Diseases, St John Hospital and Medical Center, Detroit, Michigan 48236, USA. Joel.Fishbain@stjohn.org
Abstract:
Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose resistance patterns result in significant challenges for the clinician. Despite the prevalence and interest in A. baumannii infections, there is relatively limited well-controlled scientific data to help the clinician select optimal empirical and subsequent targeted therapy for a variety of infections. We will review the currently available antimicrobial agents and discuss the clinical data supporting the use of the various agents.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acute Pyelonephritis I: Introduction
